The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorKolding Sygehus

About this trial

Nephrotic syndrome (NS) is characterized by gross proteinuria (\>3.5 g/day), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased morbidity and mortality.

The study aim is to investigate the role of the protein convertase subtilisin/kexin type 9 (PCSK9) in hyperlipidemia of NS, which has been suggested to play an important role. This is done by testing the following hypotheses:

1. PCSK9 is increased in patients with NS and hyperlipidemia compared to kidney-healthy controls 2. The level of PCSK9 in plasma correlates to the degree of proteinuria. 3. PCSK9 i increased in the kidney tissue of patients with NS

The study will compare plasma levels of PCSK9 in correlation with degree of protein in the urine between test persons with NS and kidney healthy controls. Furthermore the investigators will study the the degree of PCSK9 in the kidney in biopsies obtained from test persons with nephrotic syndrome and test persons without proteinuria.

Eligibility criteria

Qualifiers

18 years old

Patients admitted to the Medical Department and/or the Medical Emergency Department, Kolding Sygehus.

Disqualifiers

Refusal to give informed consent

Treatment with PCSK9 inhibitors

Any acute or chronic condition that would limit the ability of the patient to participate in the study

Control group: proteinuria

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

75 Participants
are grouped into 3 trial groups

Sponsors and collaborators

Kolding Sygehus

Lead sponsor

Odense University Hospital

Collaborator

Vejle Hospital

Collaborator